Skip to main content
Download PDF

Dopamine D1- and D2-like receptors oppositely regulate lifespan via a dietary restriction mechanism in Caenorhabditis elegans

BMC Biology volume 20, Article number: 71 (2022) Cite this article

Abstract

Background

Despite recent progress in understanding the molecular mechanisms regulating aging and lifespan, and the pathways involved being conserved in different species, a full understanding of the aging process has not been reached. In particular, increasing evidence suggests an active role for the nervous system in lifespan regulation, with sensory neurons, as well as serotonin and GABA signaling, having been shown to regulate lifespan in Caenorhabditis elegans (C. elegans). However, the contribution of additional neural factors, and a broad understanding of the role of the nervous system in regulating aging remains to be established. Here, we examine the impact of the dopamine system in regulating aging in C. elegans.

Results

We report that mutations of DOP-4, a dopamine D1-like receptor (D1R), and DOP-2, a dopamine D2-like receptor (D2R) oppositely affected lifespan, fast body movement span, reproductive lifespan, and developmental rate in C. elegans. Activation of D2R using aripiprazole, an antipsychotic drug, robustly extended both lifespan and healthspan. Conversely, inhibition of D2R using quetiapine shortened worm lifespan, further supporting the role of dopamine receptors in lifespan regulation. Mechanistically, D2R signaling regulates lifespan through a dietary restriction mechanism mediated by the AAK-2-DAF-16 pathway. The DAG-PKC/PKD pathway links signaling between dopamine receptors and the downstream AAK-2-DAF-16 pathway to transmit longevity signals.

Conclusions

These data demonstrated a novel role of dopamine receptors in lifespan and dietary restriction regulation. The clinically approved antipsychotic aripiprazole holds potential as a novel anti-aging drug.

Background

The biological mechanisms of aging are still not well-understood, despite several conserved aging-regulatory pathways that have been identified from yeasts to humans [1]. Increasing evidence suggests that the nervous system plays an active role in the aging process. For example, studies have shown that sensory neurons play an essential role in lifespan regulation [2, 3]. Serotonin signal was reported to antagonistically modulate longevity through different serotonin receptors [4]. Recently, inhibitory neurons gamma-aminobutyric acid (GABA) signaling has also been found to regulate lifespan in C. elegans [5]. However, much remains to be learned concerning the role of the nervous system in the regulation of the aging process.

Whether the dopamine system regulates the aging process and lifespan is unclear. Dopamine is a biogenic amine neurotransmitter, which primarily modulates behavioral outputs in response to environmental conditions [6, 7]. For example, the dopamine system functions in behaviors like reward-seeking and physical mobility and is known to be vulnerable to the effects of aging. Once released from presynaptic terminals, dopamine activates two classes of G protein-coupled receptors: D1 and D2 classes of dopamine receptors [8]. In C. elegans: DOP-1 and DOP-4 belong to D1-like dopamine receptors (D1R), while DOP-2 and DOP-3 belong to D2-like dopamine receptors (D2R) [9,10,11]. A previous study showed that worms bearing a mutation in a dopamine biosynthesis gene cat-2 had a normal lifespan, suggesting that solely reducing dopamine production does not affect longevity [4]. However, because D1R and D2R oppositely regulate a series of behaviors in C. elegans, including decision-making, basal slowing, and food response [12,13,14], it is important to determine the specific roles of each of the dopamine receptors in regulating the lifespan of C. elegans.

Because of its short lifespan, observable age-related phenotypes, and conserved aging-related biological pathways [15, 16], C. elegans is one of the most widely used model organisms to study aging. Despite its simple nervous system, C. elegans possesses a conserved dopamine system to that of the mammalian nervous system, including biosynthetic enzymes responsible for dopamine synthesis, mechanisms for synaptic release, and the expression of dopamine receptors [17]. These features made C. elegans a suitable genetic model system for investigating the role of the dopamine system in longevity.

In the present study, we demonstrate that dopamine D1- and D2-like receptors oppositely regulate worm lifespan through a dietary restriction (DR) mechanism. Using molecular genetics approach and pharmacological tools, we teased out how dopamine receptors send longevity signals through their G-protein-coupled signaling transduction pathways to downstream DR-related pathway. Our findings uncover a novel mechanism of dopamine signaling in DR and lifespan regulation. Notably, aripiprazole, a clinically widely used antipsychotic drug, robustly extend both the lifespan (> 50%) and healthspan (> 80%) of C. elegans by activating the dopamine receptor-mediated pathway. The surprise finding of aripiprazole holds promise for further development as a potentially safe, novel anti-aging drug.

Results

Dopamine D1- and D2-like receptors have opposite effects on the lifespan of C. elegans

To determine the role of each dopamine receptor in worm lifespan, worm strains carrying mutations on each of the four dopamine receptor genes, including dop-1, dop-2, dop-3, and dop-4, were used for lifespan assay. Intriguingly, the dop-2 mutant showed a significantly reduced lifespan (− 11.8%, P < 0.0001) than N2 animals, whereas the dop-4 mutant was significantly long-lived (+ 29.4%, P < 0.0001) compared with N2 animals. The dop-1 and dop-3 mutants also showed changes in lifespan (at + 5.9% and − 8.8%, respectively) compared with N2 animals, which were not statistically significant (P = 0.0765, P = 0.2468, respectively, Fig. 1A). These data demonstrated that signaling through D2R (DOP-2) extends lifespan while signal through D1R (DOP-4) shortens it. The lack of statistical significance in dop-1 and dop-3 mutants-induced changes in lifespan indicated that DOP-4 and DOP-2 are the major subtypes of D1R and D2R in regulating lifespan, respectively.

Fig. 1
figure 1

Dopamine D1- and D2-like receptors oppositely regulate lifespan in C. elegans. A Survival curves of different worm strains cultured at 20 °C (mutant strains were compared with the wild-type N2: ns = not significant; **** indicated P < 0.0001, log-rank test). B Fast body movement spans of different worm strains cultured at 20 °C (mutant strains were compared with the N2: **, P < 0.01, log-rank test). C Progeny produced per day by different worm strains. D The number of worms with different reproductive lifespans. E The developmental stage of different worm strains reached 2.5 days post-hatching. (see Additional file 2 for supporting data). Experiments were performed in three independent biological replicates

Full size image

Lifespan extension has been associated with slowed locomotory and reproductive aging, as well as delayed development [18,19,20]. To further understand the roles of dopamine receptors in the aging process, we next examined the fast body movement span, reproductive lifespan, and developmental rate of these mutants. Compared to N2 animals, the dop-2 mutant showed a shorter reproductive lifespan and fast body movement span than N2 animals, whereas the dop-4 mutant had an extended reproductive lifespan and fast body movement span (Fig. 1B–D). The dop-2 mutant developed faster, whereas the dop-4 mutant showed a slower developmental rate (Fig. 1D). These data further supported the idea that specific dopamine receptors played a selective and unique role in lifespan regulation.

Pharmacological activation or inhibition of D2R exerts opposite effects on the lifespan of C. elegans

To further confirm the role of D2R in extending lifespan in C. elegans, a pharmacological approach employing aripiprazole, a D2R agonist, and quetiapine, a D2R antagonist, were used to determine the effect on worm lifespan [21, 22]. Wild-type N2 worms were treated with aripiprazole and quetiapine at concentrations ranging from 3 to 100 μM. Robust lifespan extensions were observed in aripiprazole-treated worms. Aripiprazole at 3 μM concentration significantly extended the median lifespan of N2 worms by 21.1% (P < 0.0001). Worms exposed to 100 μM of aripiprazole reached a maximum lifespan extension of up to 52.6% (P < 0.0001) (Fig. 2A). In contrast, quetiapine treatment dose-dependently shortened worm lifespan (Fig. 2B). Dose-response curves are shown in Fig. 2C. These findings further support a key role of D2R in regulating worm lifespan.

Fig. 2
figure 2

Pharmacological activation or inhibition of D2R exerts opposite effects on the lifespan of C. elegans. A Survival curves of wild-type (N2) worms cultured at 20 °C on NGM plates containing different concentrations of aripiprazole (Ari). DMSO treatment was used as a control. B Survival curves of N2 worms treated with the indicated concentrations of quetiapine (Que) or DMSO at 20 °C. (aripiprazole and quetiapine treatment were compared with the DMSO treatment: **indicated P < 0.01. ***, P < 0.001. ****, P < 0.0001, log-rank test). C Dose-response curve of aripiprazole (Ari) and quetiapine (Que) treatment. (see Additional file 2 for supporting data). Experiments were performed in three independent biological replicates

Full size image

Aripiprazole extends the lifespan of C. elegans through DOP-2

To determine whether aripiprazole-mediated lifespan extension is dependent on D2R, we first tested the drug on dopamine synthesis-deficient mutant cat-2. Aripiprazole failed to extend lifespan in the cat-2 mutant (Fig. 3A), suggesting that the lifespan extension effect of aripiprazole requires dopamine signaling. We next employed a dop-2; dop-3 double mutant and found that it was insensitive to aripiprazole treatment (Fig. 3B). To investigate which of these two receptors contributes to the lifespan extension effect, we tested every single mutant. The results showed that aripiprazole did not extend the lifespan of dop-2 mutant (Fig. 3C), while dop-3 mutant showed a robust lifespan extension upon aripiprazole treatment (Fig. 3D). These findings demonstrated that lifespan extension by aripiprazole was conferred by its action on DOP-2.

Fig. 3
figure 3

Aripiprazole extends the lifespan of C. elegans through DOP-2. Survival curves of mutant cat-2 (A); dop-2; dop-3 (B); dop-2 (C); dop-3 (D) treated with 100 μM of aripiprazole or DMSO at 20 °C (comparison between DMSO and aripiprazole (Ari) treatment: ns = not significant with P > 0.05; ****indicated P < 0.0001, log-rank test) (see Additional file 2 for supporting data). Experiments were performed in three independent biological replicates

Full size image

Aripiprazole mediates lifespan extension through D2R signaling

DOP-2 signals through Gαo pathways [8, 23]. To identify DOP-2 downstream effectors mediating the aripiprazole-induced pro-longevity effect, we first tested a mutant lacking GOA-1, the C. elegans ortholog of Gαo protein [24]. As expected, GOA-1 is required for aripiprazole-induced extension of lifespan (Fig. 4A). D2R inhibits adenylyl cyclase and thus suppresses the production of intracellular cyclic AMP (cAMP) and the activity of protein kinase A (PKA) [25]. The cAMP-PKA pathway has been shown to mediate lifespan and DR responses [26,27,28]. acy-1 encodes adenylyl cyclase and regulates cAMP production in C. elegans [29]. The C. elegans genome encodes a PKA catalytic subunit (KIN-1) and a PKA regulatory subunit (KIN-2) [30,31,32]. The binding of cAMP to KIN-2 results in the release of active KIN-1 [29]. The results showed that the lifespan extension by aripiprazole treatment was only partly dependent on ACY-1 and KIN-1 (Fig. 4B, C).

Fig. 4
figure 4

Aripiprazole mediates lifespan extension through D2R signaling. Survival curves of mutant goa-1 (A), acy-1 (B), kin-1 (C), dgk-1 (D), pkc-1 (E), pkc-2 (F), pkc-3 (G), tpa-1 (H), dkf-1 (I), dkf-2 (J), egl-30 (K), and egl-8 (L) treated with 100 μM of aripiprazole (Ari) or DMSO at 20 °C (comparison between DMSO and Ari treatment: ns = not significant with P > 0.05; **indicated P < 0.01. ****, P < 0.0001 with log-rank test) (see Additional file 2 for supporting data). Experiments were performed in three independent biological replicates

Full size image

Another important downstream factor of GOA-1 is DGK-1, the C. elegans ortholog of diacylglycerol kinase [33]. The GOA-1/DGK-1 pathway inhibits the production of diacylglycerol (DAG), thus antagonizes the effect of the EGL-30/EGL-8 pathway [34, 35]. DGK-1 was indeed essential for aripiprazole-induced lifespan extension (Fig. 4D). DAG could activate downstream molecules, including protein kinase C (PKC) and protein kinase D (PKD) [36, 37]. The worm genome encodes four PKC homologs (tpa-1, pkc-1, pkc-2 and pkc-3) and two PKD homologs (dkf-1 and dkf-2) [5]. Among the four PKC homologs, pkc-1, pkc-3 and tpa-1 were required for aripiprazole to extend lifespan, whereas pkc-2 were dispensable (Fig. 4E–H). For the two PKD homologs, aripiprazole-mediated lifespan extension was dependent on dkf-1 rather than dkf-2 (Fig. 4I, J). These findings suggested that aripiprazole may extend lifespan through both PKC and PKD. To further confirm the role of the DGK-PKC/PKD pathway, we also tested egl-30 and egl-8 mutants, both of which are supposed to have impaired DAG production and thus reduced PKC/PKD activity [34]. As expected, aripiprazole failed to extend lifespan in both mutants (Fig. 4K, L), further supported the key role of the DGK-PKC/PKD pathway in aripiprazole-mediated lifespan extension. Taken together, aripiprazole mediates lifespan extension through GOA-1-DGK-1-PKC/PKD, but may only be partly dependent on the cAMP-PKA pathway.

Aripiprazole extends worm lifespan through a Dietary Restriction (DR) mechanism

DR robustly delays the aging process in many species [38]. Several DR-related phenotypes in C. elegans included increased healthspan, decreased feeding behavior, reduced brood size, prolonged reproduction period, and reduced lipid storage [39, 40]. Therefore, we wanted to know whether dopamine signaling and aripiprazole treatment can modulate lifespan through DR mechanisms. We first tested aripiprazole on a long-lived eat-2 mutant, a genetic model of DR with a deficit in pharyngeal pumping [41]. Aripiprazole did not further extend the lifespan of the eat-2 mutant (Fig. 5A), indicating that the lifespan benefits of aripiprazole were indeed conferred by a DR mechanism. Several DR-related phenotypes were also examined. Besides the extended lifespan, the healthspan reflecting the quality of the extended lifespan was also of great significance for healthy aging. Aripiprazole increased the healthspan of C. elegans in a dose-dependent manner which was coupled with its effect on lifespan. Aripiprazole at 100 μM resulted in a maximum increment (87.5%) on the healthspan of N2 animals (Fig. 5B). Aripiprazole treatment also reduced the total progeny produced per worm, even with a more extended reproduction period (Fig. 5C, D). Furthermore, oil red O staining showed that aripiprazole-treated worms had reduced lipid accumulation (Fig. 5E, F). Pharyngeal pumping rate positively correlates with food intake in C. elegans. One direct cause of the DR-like effect is reduced food intake resulted from decreased pharyngeal pumping rate, like that observed in the eat-2 mutant. As shown in Fig. 5G, aripiprazole treated N2 worms displayed a reduced pharyngeal pumping rate, further suggested that aripiprazole triggered a DR-like state in C. elegans.

Fig. 5
figure 5

Aripiprazole extends worm lifespan through a dietary restriction mechanism. A Survival curves of the eat-2 mutant treated with 100 μM of aripiprazole (Ari) or DMSO at 20 °C (comparison between DMSO and Ari treatment: ns = not significant, P > 0 .05. **, P < 0.01. ****, P < 0.0001, log-rank test). B Fast body movement spans of wild-type (N2) worms cultured at 20 °C on NGM plates containing indicated concentrations of aripiprazole (Ari) or DMSO. C, D Changes in brood size (C) and reproductive span (D) of N2 animals treated with or without 100 μM of aripiprazole (Ari) (comparison between DMSO and aripiprazole (Ari) treatment: ****, P < 0.0001, t-test). E Representative images of ORO staining of worms treated with or without aripiprazole (Ari) for 7 days. Scale bar = 200 μm. F Relative ORO intensity of worms treated with or without aripiprazole for 7 days (comparison between DMSO and aripiprazole (Ari) treatment: ****, P < 0.0001, t-test). G Pharyngeal pumping rate of N2 worms treated with 100 μM of aripiprazole (Ari) or DMSO for 5 days (comparison between DMSO and Ari treatment: **** indicated P < 0.0001, t-test). (see Additional file 2 for supporting data). The brood size assay was performed in two independent biological replicates. Other experiments were performed in three independent biological replicates

Full size image

Aripiprazole mediates DR-like lifespan extension through the AAK-2-DAF-16 pathway

To further dissect the possible mechanisms of aripiprazole-mediated DR-like lifespan extension, we examined DAF-16, a C. elegans homolog of mammalian FOXO transcription factor known to play a central role in lifespan and DR regulation [42]. Remarkably, the lifespan extension effect of aripiprazole was abolished entirely in the daf-16 mutant (Fig. 6A). DAF-16 locates in the cytosol under normal conditions. Once activated, DAF-16 becomes translocated to the nucleus to trigger the transcription of various genes that regulate stress resistance, metabolism, reproduction, and longevity. Indeed, TJ356 worms with green fluorescent protein (GFP)-tagged DAF-16 showed an increased accumulation of DAF-16 in the nucleus once treated with aripiprazole (Fig. 6B, C), suggesting that aripiprazole mediates DR-like lifespan extension through DAF-16.

Fig. 6
figure 6

Aripiprazole mediates DR-like lifespan extension through the AAK-2-DAF-16 pathway. A Survival curves of the daf-16 mutant treated with 100 μM of aripiprazole (Ari) or DMSO at 20 °C (comparison between DMSO and aripiprazole (Ari) treatment: ns = not significant with P > 0.05, log-rank test). B The representative images of worms having cytosolic, intermediate, and nuclear DAF-16 localization in TJ356 transgenic strains. Scale bar = 50 μm. C The percentile of TJ356 animals treated with 100 μM aripiprazole (Ari) or DMSO displaying cytosolic, intermediate, or nuclear localization. D–J Survival curves of mutant daf-2 (D), age-1 (E), akt-1 (F), akt-2 (G), sir-2.1 (H), aak-2 (I), par-4 (J) treated with 100 μM of aripiprazole (Ari) or DMSO at 20 °C (comparison between DMSO and aripiprazole (Ari) treatment: ns = not significant with P > 0.05. ** indicated p < 0.01. ****, p < 0.0001, log-rank test) (see Additional file 2 for supporting data). Experiments were performed in three independent biological replicates

Full size image

In DR-like mechanism, insulin/insulin-like growth factor 1 (IGF-1) signaling, silent information regulator 2 (SIR2), and AMP-activated kinase (AMPK) may act upstream of DAF-16 [42]. To determine if aripiprazole extends lifespan by acting on the insulin/IGF-1 signaling pathway, we first tested the long-lived insulin-like receptor mutant daf-2. Aripiprazole failed to extend the lifespan of this mutant (Fig. 6D), suggesting an essential role of DAF-2 in aripiprazole-mediated lifespan extension. The effects of aripiprazole on age-1, akt-1, and akt-2 mutants were also examined. However, aripiprazole treatment extended the lifespan of all three mutants by 50.0%, 73.7%, and 50.0%, respectively, which was at a level similar to that of the N2 animals (52.6%) (Fig. 6E–G). These results indicated that aripiprazole did not primarily signal through the insulin/IGF-1 signaling pathway to extend C. elegans lifespan. Moreover, aripiprazole increased the lifespan of sir-2.1 mutant to a similar extent to N2 animals (Fig. 6H), demonstrating that aripiprazole-mediated lifespan extension was also independent of SIR-2.1.

Aripiprazole has been shown to activate mammalian AMPK in PC12 cells [43, 44]. We, therefore, hypothesized that aripiprazole might function through AAK-2 to mediate the extension of lifespan. As shown in Fig. 6I, aripiprazole failed to extend the lifespan of the aak-2 mutant, suggesting that aak-2 is required for the effects of aripiprazole on lifespan. We further tested a mutant bearing a mutation in C. elegans liver kinase B1 (LKB1) homolog PAR-4, an upstream kinase of AMPK. The par-4 mutant displayed no lifespan extension upon aripiprazole-treatment (Fig. 6J), which further supported the hypothesis that aripiprazole-mediated lifespan extension requires the activity of AAK-2.

Discussion

In the present study, we showed that D1R (dop-4) and D2R (dop-2) mutations of C. elegans oppositely affected worm lifespan in that the dop-2 mutant was short-lived, whereas the dop-4 mutant was long-lived. Pharmacological activation of DOP-2 using aripiprazole robustly extended worm lifespan, whereas inhibition of DOP-2 using quetiapine resulted in shortened lifespan, supporting the selective role of specific dopamine receptors in lifespan regulation. Our data demonstrated that DOP-2 is the major subtype of D2R, and DOP-4 was the major subtype of D1R to regulate lifespan since mutations on the other two dopamine receptors failed to show statistically significant impacts on lifespan. These findings were further supported by the fact that aripiprazole-induced lifespan extension required DOP-2 instead of DOP-3. Mechanistically, dopamine receptors regulate lifespan through a DR mechanism mediated by the AAK-2-DAF-16 pathway. The DAG-PKC/PKD pathway served as a link between dopamine receptors and the AAK-2-DAF-16 pathway to transmit longevity signals. Together, these data represent a novel role of the dopamine system in lifespan regulation, a schematic diagram illustrating the possible mechanism of dopamine system extension of lifespan was shown in Fig. 7.

Fig. 7
figure 7

A schematic diagram of the possible mechanism of dopamine receptor signaling-mediated lifespan regulation. In C. elegans, DOP-2 signaling extends lifespan while DOP-4 signaling shortens lifespan. Pharmacological activation of DOP-2 using aripiprazole extends lifespan, whereas inhibition of DOP-2 using quetiapine shortens lifespan. Aripiprazole extends lifespan through a DR mechanism mediated by the AAK-2-DAF-16 pathway. The DAG-PKC/PKD pathway served as a link between dopamine receptors and the AAK-2-DAF-16 pathway to transmit longevity signals. The role of DOP-4 in lifespan regulation requires further investigation

Full size image

A previous study reported that several dopamine receptor agonists could extend worm lifespan [45]. The authors found that these compounds did not inhibit the growth of feeding bacterial, indicating that they may extend lifespan by directly acting on the worms [45]. However, the detailed molecular mechanism was unknown. In the present study, we found that aripiprazole extends lifespan by activating the D2R-mediated DR mechanism, indicating that lifespan extensions caused by aripiprazole and possibly other dopamine receptor agonists should be due to their direct effects of modulating worm dopamine signaling; nonetheless, future studies are warranted. In addition, although aripiprazole treatment induced a slight reduction in pharyngeal pumping rate, consistent with a previous report [46], this is also unlikely to be the major cause of DR. First, NP-1, a drug inducing potent lifespan extension through a dietary restriction mechanism, caused a significant reduction in pharyngeal pumping rate in worms but failed to alter food intake [47]. Second, robust lifespan extension usually requires a more significant reduction in pharyngeal pumping rate. The eat-2(ad1116) mutant has a 57% longer lifespan than the wild-type animals, similar to that of aripiprazole-treated worms, but featuring a nearly 90% reduction in pharyngeal pumping rate [41, 48]. Two eat-18 mutants with 70-80% reduction in pharyngeal pumping rate only display 15% and 38% lifespan extension, respectively [41, 48]. Taken together, we provide a novel molecular mechanism explaining how dopamine receptor agonists extend C. elegans lifespan. The significant lifespan extension effect caused by D2R activation or loss of D1R signaling should be due to direct activation of intrinsic DR pathways in C. elegans instead of altered food intake or inhibited growth of feeding bacterial. Whether D1R agonists and antagonists can affect C. elegans lifespan needs further investigation.

As a reasonable extrapolation from the mammalian data that shows the agonistic action of aripiprazole on D2R, aripiprazole should be able to bind DOP-2 in C. elegans and stimulate the downstream pathways in the absence of endogenous dopamine. However, interestingly, our results showed that aripiprazole failed to extend the lifespan of the cat-2 mutant, suggesting that a certain dopamine level may be required for aripiprazole to extend lifespan. A possible explanation is that instead of being a conventional agonist of DOP-2, aripiprazole may act as an allosteric modulator whose binding results in a conformational change of DOP-2 and subsequently enhanced affinity to dopamine. Further studies are needed to clarify the agonistic action of aripiprazole on DOP-2 in C. elegans. Notably, our results showed that aripiprazole showed a biphasic effect on dop-2 mutant that is not presented on other cases. This is also an interesting question that demands further investigation.

The conclusion that aripiprazole extends lifespan through a DR mechanism is supported by the fact that aripiprazole not only failed to extend the lifespan of the eat-2 mutant but also induced DR phenotypes including prolonged healthspan, reduced brood size, extended reproductive period as well as decreased lipid storage. Further investigation demonstrated that aripiprazole-mediated DR response was dependent on the AAK-2-DAF-16 pathway. DR is subjected to the regulation of multiple genetic pathways, and different DR regimens may elicit different pathways to confer lifespan extension. For example, Greer et al. described that sDR (dilution of feeding bacterial on solid plates) and DP (dilution of peptone) extend lifespan through the AAK-2-DAF-16 pathway, whereas other DR regimens could activate SKN-1, PHA-4 or HSF-1 [49]. In the present study, aripiprazole-mediated DR responses are mechanistically more similar to those induced by sDR or DP. Further studies are needed to identify the precise mechanism of the selectivity of DR on various genetic pathways.

How dopamine signaling is transmitted to the AAK-2-DAF-16 pathway to regulate lifespan is an interesting question. The activity of AMPK can be regulated by a series of upstream kinases, such as PKA, protein kinase B (AKT), PKC, PKD, and LKB1. LKB1 phosphorylates AMPK at Thr-172 for activation. Conversely, PKA, PKC, and PKD phosphorylate AMPK at Ser-485/491 to inhibit its activity [36, 37, 50]. Although we found that LKB1 is required for aripiprazole to extend lifespan, it is unlikely to be directly linked with dopamine receptors. AKT was also excluded since both AKT-1 and AKT-2 were dispensable for aripiprazole-mediated lifespan extension. The cAMP-PKA pathway, a well-known downstream effector of D2R and a target of aripiprazole [51], is also unlikely to play a primary role since ACY-1 and KIN-1 are only partially required for aripiprazole-mediated extension of lifespan. These data indicated that other G protein pathways might be involved.

We found that one possible downstream effector of the dopamine receptors is DAG, which is differentially regulated by Gαq signaling pathway encoded by egl-30 and egl-8, and the Gαo signaling pathway encoded by goa-1 and dgk-1. A previous study found that GABA receptor GBB-1 modulates lifespan through the EGL-30-EGL-8-DAF-16 pathway, suggesting a lifespan regulatory role of Gαq signaling pathway [5]. However, the role of Gαo signaling pathway in lifespan regulation has not been reported. Our data demonstrated that aripiprazole-mediated lifespan extension requires all proteins in both Gαq and Gαo signaling pathways. The loss of D1R signaling or activation of D2R signaling may lead to inhibition of worm PKCs and PKDs, and subsequent activation of AAK-2-DAF-16-mediated lifespan extension. Conversely, loss of D2R signaling leads to AAK-2 inhibition and thus shortened lifespan. Our results demonstrated that aripiprazole showed functional selectivity at different C. elegans PKC/PKD isoforms. This may be due to the different expression patterns of these isoforms and the tissue-specific effects of aripiprazole.

Dopamine receptors are widely expressed in the nervous system [9]. From mutation studies, it is not feasible to exclude the possibility that alterations of D1R or D2R signaling affect lifespan through a non-cell-autonomous manner. This notion is strengthened by a recent study showing that an olfactory circuit involving dopamine, serotonin, and octopamine signaling mediates dietary restriction by transmitting food odor signals to the gut in C. elegans [52]. However, it is known that worm D1R and D2R (DOP-1-4) are not involved in food odor-mediated dietary restriction response. Further investigation is warranted to identify the precise mechanism of D1R and D2R-mediated DR response.

Previous studies based on liquid media have reported that several antidepressants, including mianserin, could extend worm lifespan, mainly by blocking serotonin receptors [53,54,55]. .A recent work showed that the lifespan-extending effect of mianserin also involves dopaminergic signaling [56]. Despite the antipsychotics, including aripiprazole, have been clinically used for decades, their direct effect on lifespan remains unclear. Some reported that antipsychotics disrupt the development of C. elegans [57]. Others reported that antipsychotics, including aripiprazole, could activate the Akt pathway through DAF-2, implying that they may negatively regulate lifespan [58]. Nevertheless, we found that aripiprazole could robustly extend both the lifespan and healthspan of C. elegans through a mechanism other than the Akt pathway, but related to dopamine receptor-mediated DR responses. Since DR has been reported to delay the development of C. elegans [40], our results may explain the previous finding that treating worms with several other antipsychotics resulted in delayed development, and hinting that starting the treatment from adulthood may be essential for optimizing the pro-longevity of aripiprazole and avoiding its possible developmental toxicity. Notably, aripiprazole has very good long-term safety and tolerability [59, 60]. Moreover, besides its therapeutic effect on psychiatric disorders, aripiprazole also showed a neuroprotective effect, cognitive-enhancing effect, and therapeutic effect against Alzheimer’s disease [61,62,63]. Therefore, aripiprazole holds potential as a novel safe anti-aging drug.

Conclusions

Taken together, our findings uncover a novel role of dopamine signaling in lifespan regulation. Genetic inhibition of D1R or pharmacological activation of D2R using aripiprazole could robustly extend both lifespan and healthspan in C. elegans. The clinically proved good long-term safety of aripiprazole as well as the fact that the dopamine system and its downstream DR-related pathways is highly conserved among species support the further translation of our finding into humans. Moreover, developing interventions targeting the dopamine system may be a new direction for aging research which aims to benefit human health and longevity.

Methods

Nematode C. elegans strains and their maintenance

All strains were obtained from the Caenorhabditis Genetics Center (CGC, University of Minnesota) and maintained at appropriate temperature on solid nematode growth medium (NGM) plates seeded with E. coli OP50. Strains used in this study are described in Additional file 1: Table S1.

Preparation of reagents

Aripiprazole and quetiapine, purchased from Meilunbio (Dalian, China), were dissolved in dimethyl sulfoxide (DMSO) as stocks. Drugs were added to the liquid NGM before pouring plates. A final DMSO concentration of 0.1% (v/v) was maintained under all conditions.

Lifespan, fast body movement span, and pharyngeal pumping assays

Worms were cultured for three generations without starvation before lifespan assays. All lifespan assays were performed at 20 °C unless specified. Synchronized late L4 larvae were transferred to lifespan assay plates supplemented with 50 μM of 5-fluoro-2′-deoxyuridine (FUdR, Sigma) to prevent self-fertilization (see Additional file 2: Table S2 for n numbers for each experiment). The day worms were transferred to lifespan assay plates was set as day 0 for an experiment, and worms were counted every 2–3 days. Animals that did not respond to gently prodding by platinum wire were scored as dead. Animals were censored from the experiment if they crawled off the plate or died from vulva bursting or internal hatching (bagging). Lifespan assays were performed in three independent biological replicates. Fast body movement spans were measured along with lifespan assays. Worms with continuous sinusoidal movement when responding to tapping the plates were classified as having fast body movement. For the pharyngeal pumping assay, pharyngeal pumps in the 20s- intervals were recorded under the microscope at day 5 of lifespan assays.

DAF-16 translocation assay

Strain TJ356 daf-16(zls356) IV was used to monitor the translocation of DAF-16:GFP. In each experiment, age-synchronized L4 larvae were treated with 100 μM of aripiprazole or DMSO for 24 h in the same way as described in the lifespan assays. Then, worms were mounted on glass slides with a drop of 0.1% sodium azide and capped with coverslips. Images of the DAF-16:GFP signal was quickly taken with a Nikon TiE fluorescent microscope. Animals were scored as having cytosolic or nuclear localization when localization was observed throughout the entire body or intermediate localization when a mixed distribution pattern was shown. This assay was repeated at least three times and scored by two different individuals.

Brood size and reproductive lifespan assays

Worms (n = 10 or 15) were transferred to fresh NGM plates with bacterial lawn. Each worm was placed in one plate and transferred to a fresh NGM plate every 24 h until egg-laying had ceased. The number of hatched worms on each day was counted after 72 h of incubation at 20 °C. The brood size of each worm was the total number of hatched progenies during the assay. The reproductive lifespan of each worm was the time period that it was capable of laying eggs.

Developmental rate assay

Synchronized eggs of each strain were placed on NGM plates and cultured at 20 °C. Developmental stages of animals were visually inspected under a stereoscope after 2.5 days. 50 to 100 animals were scored for each strain.

Oil red O (ORO) staining

About 1000 age-synchronized L4 larvae were transferred to 6 NGM plates containing 100 μM of aripiprazole or DMSO and cultured for 7 days at 20 °C. Worms were collected, washed with phosphate buffered saline (PBS), and fixed in 2 × MRWB-PFA. Then, worms were washed and dehydrated in isopropanol. After that, isopropanol was replaced with a new ORO solution. After ORO staining, animals were mounted on slides, and images were taken by a Carl Zeiss Axio Imager 2.

Statistical analysis

The lifespan assays were analyzed using the Kaplan-Meier method and the log-rank test. Brood size assay, pharyngeal pumping rate assay, and ORO staining were analyzed using unpaired t-tests. Error bars were presented as mean ± SEM. Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, San Diego, CA).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files. Supporting data are included in Additional file 2.

Abbreviations

AKT :

Protein kinase B

AMPK :

AMP-activated protein kinase

Ari :

Aripiprazole

cAMP :

Cyclic AMP

C. elegans :

Caenorhabditis elegans

DAG :

Diacylglycerol

D1R :

Dopamine D1-like receptor

D2R :

Dopamine D2-like receptor

DMSO :

Dimethyl sulfoxide

DR :

Dietary restriction

FUdR :

5-Fluoro-2′-deoxyuridine

GABA :

Gamma-aminobutyric acid

GFP :

Green fluorescent protein

IGF-1 :

Insulin-like growth factor 1

NGM :

Nematode growth medium

LKB1 :

Liver kinase B1

ORO :

Oil red O

PKA :

Protein kinase A

PKC :

Protein kinase C

PKD :

Protein kinase D

Que :

Quetiapine

SIR2 :

Silent information regulator 2

References

  1. Pan H, Finkel T. Key proteins and pathways that regulate lifespan. J Biol Chem. 2017;292(16):6452–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jeong DE, Artan M, Seo K, Lee SJ. Regulation of lifespan by chemosensory and thermosensory systems: findings in invertebrates and their implications in mammalian aging. Front Genet. 2012;3:218.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Allen EN, Ren J, Zhang Y, Alcedo J. Sensory systems: their impact on C. elegans survival. Neuroscience. 2015;296:15–25.

    Article  CAS  PubMed  Google Scholar 

  4. Murakami H, Murakami S. Serotonin receptors antagonistically modulate Caenorhabditis elegans longevity. Aging Cell. 2007;6(4):483–8.

    Article  CAS  PubMed  Google Scholar 

  5. Chun L, Gong J, Yuan F, Zhang B, Liu H, Zheng T, et al. Metabotropic GABA signalling modulates longevity in C. elegans. Nat Commun. 2015;6:8828.

    Article  CAS  PubMed  Google Scholar 

  6. Rivard L, Srinivasan J, Stone A, Ochoa S, Sternberg PW, Loer CM. A comparison of experience-dependent locomotory behaviors and biogenic amine neurons in nematode relatives of Caenorhabditis elegans. BMC Neurosci. 2010;11:22.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004;5(6):483–94.

    Article  CAS  PubMed  Google Scholar 

  8. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182–217.

    Article  CAS  PubMed  Google Scholar 

  9. Chase DL, Pepper JS, Koelle MR. Mechanism of extrasynaptic dopamine signaling in Caenorhabditis elegans. Nat Neurosci. 2004;7(10):1096–103.

    Article  CAS  PubMed  Google Scholar 

  10. Suo S, Ishiura S, Van Tol HH. Dopamine receptors in C. elegans. Eur J Pharmacol. 2004;500(1-3):159–66.

    Article  CAS  PubMed  Google Scholar 

  11. Sugiura M, Fuke S, Suo S, Sasagawa N, Van Tol HH, Ishiura S. Characterization of a novel D2-like dopamine receptor with a truncated splice variant and a D1-like dopamine receptor unique to invertebrates from Caenorhabditis elegans. J Neurochem. 2005;94(4):1146–57.

    Article  CAS  PubMed  Google Scholar 

  12. Hills T, Brockie PJ, Maricq AV. Dopamine and glutamate control area-restricted search behavior in Caenorhabditis elegans. J Neurosci. 2004;24(5):1217–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wang DY, Yu YL, Li YX, Wang Y, Wang DY. Dopamine receptors antagonistically regulate behavioral choice between conflicting alternatives in C-elegans. PLoS One. 2014;9(12):e115985.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Suo S, Culotti JG, Van Tol HH. Dopamine counteracts octopamine signalling in a neural circuit mediating food response in C. elegans. EMBO J. 2009;28(16):2437–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Olsen A, Vantipalli MC, Lithgow GJ. Using Caenorhabditis elegans as a model for aging and age-related diseases. Ann N Y Acad Sci. 2006;1067:120–8.

    Article  CAS  PubMed  Google Scholar 

  16. Uno M, Nishida E. Lifespan-regulating genes in C. elegans. Npj Aging Mech Dis. 2016;2:16010.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science. 1998;282(5396):2028–33.

    Article  CAS  PubMed  Google Scholar 

  18. Hughes SE, Huang C, Kornfeld K. Identification of mutations that delay somatic or reproductive aging of Caenorhabditis elegans. Genetics. 2011;189(1):341–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Van Raamsdonk JM, Meng Y, Camp D, Yang W, Jia XH, Benard C, et al. Decreased energy metabolism extends life span in Caenorhabditis elegans without reducing oxidative damage. Genetics. 2010;185(2):559–U263.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tissenbaum HA. Genetics, life span, health span, and the aging process in Caenorhabditis elegans. J Gerontol A Biol Sci Med Sci. 2012;67(5):503–10.

    Article  PubMed  Google Scholar 

  21. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors - focus on newer generation compounds. Life Sci. 2000;68(1):29–39.

    Article  CAS  PubMed  Google Scholar 

  22. Lopez-Munoz F, Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry. 2013;4:102.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Correa P, LeBoeuf B, Garcia LR. C. elegans dopaminergic D2-like receptors delimit recurrent cholinergic-mediated motor programs during a goal-oriented behavior. PLoS Genet. 2012;8(11):e1003015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lochrie MA, Mendel JE, Sternberg PW, Simon MI. Homologous and unique G-protein alpha subunits in the nematode Caenorhabditis-Elegans. Cell Regul. 1991;2(2):135–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Suo S, Sasagawa N, Ishiura S. Cloning and characterization of a Caenorhabditis elegans D2-like dopamine receptor. J Neurochem. 2003;86(4):869–78.

    Article  CAS  PubMed  Google Scholar 

  26. Wei M, Fabrizio P, Hu J, Ge HY, Cheng C, Li L, et al. Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet. 2008;4(1):e13.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Molin M, Yang JS, Hanzen S, Toledano MB, Labarre J, Nystrom T. Life span extension and H2O2 resistance elicited by caloric restriction require the peroxiredoxin Tsa1 in Saccharomyces cerevisiae. Mol Cell. 2011;43(5):823–33.

    Article  CAS  PubMed  Google Scholar 

  28. Kang WK, Kim YH, Kang HA, Kwon KS, Kim JY. Sir2 phosphorylation through cAMP-PKA and CK2 signaling inhibits the lifespan extension activity of Sir2 in yeast. Elife. 2015;4:e09709.

    Article  PubMed Central  Google Scholar 

  29. Schade MA, Reynolds NK, Dollins CM, Miller KG. Mutations that rescue the paralysis of Caenorhabditis elegans ric-8 (synembryn) mutants activate the G alpha(s) pathway and define a third major branch of the synaptic signaling network. Genetics. 2005;169(2):631–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lee JH, Han JS, Kong J, Ji Y, Lv XC, Lee J, et al. Protein kinase A subunit balance regulates lipid metabolism in Caenorhabditis elegans and mammalian adipocytes. J Biol Chem. 2016;291(39):20315–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gross RE, Bagchi S, Lu XY, Rubin CS. Cloning, characterization, and expression of the gene for the catalytic subunit of camp-dependent protein-kinase in Caenorhabditis-elegans - identification of highly conserved and unique isoforms generated by alternative splicing. J Biol Chem. 1990;265(12):6896–907.

    Article  CAS  PubMed  Google Scholar 

  32. Lu XY, Gross RE, Bagchi S, Rubin CS. Cloning, structure, and expression of the gene for a novel regulatory subunit of camp-dependent protein-kinase in Caenorhabditis-elegans. J Biol Chem. 1990;265(6):3293–303.

    Article  CAS  PubMed  Google Scholar 

  33. Nurrish S, Segalat L, Kaplan JM. Serotonin inhibition of synaptic transmission: G alpha(o) decreases the abundance of UNC-13 at release sites. Neuron. 1999;24(1):231–42.

    Article  CAS  PubMed  Google Scholar 

  34. Miller KG, Emerson MD, Rand JB. Goalpha and diacylglycerol kinase negatively regulate the Gqalpha pathway in C. elegans. Neuron. 1999;24(2):323–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Allen AT, Maher KN, Wani KA, Betts KE, Chase DL. Coexpressed D1- and D2-like dopamine receptors antagonistically modulate acetylcholine release in Caenorhabditis elegans. Genetics. 2011;188(3):579–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Coughlan KA, Valentine RJ, Sudit BS, Allen K, Dagon Y, Kahn BB, et al. PKD1 Inhibits AMPK2 through phosphorylation of serine 491 and impairs insulin signaling in skeletal muscle cells. J Biol Chem. 2016;291(11):5664–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Jiang LQ, Barbosa TD, Massart J, Deshmukh AS, Lofgren L, Duque-Guimaraes DE, et al. Diacylglycerol kinase-delta regulates AMPK signaling, lipid metabolism, and skeletal muscle energetics. Am J Physiol-Endoc M. 2016;310(1):E51–60.

    Google Scholar 

  38. Greer EL, Dowlatshahi D, Banko MR, Villen J, Hoang K, Blanchard D, et al. An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. Curr Biol. 2007;17(19):1646–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Houthoofd K, Johnson TE, Vanfleteren JR. Dietary restriction in the nematode Caenorhabditis elegans. J Gerontol A Biol Sci Med Sci. 2005;60(9):1125–31.

    Article  PubMed  Google Scholar 

  40. Szewczyk NJ, Udranszky IA, Kozak E, Sunga J, Kim SK, Jacobson LA, et al. Delayed development and lifespan extension as features of metabolic lifestyle alteration in C-elegans under dietary restriction. J Exp Biol. 2006;209(20):4129–39.

    Article  CAS  PubMed  Google Scholar 

  41. Lakowski B, Hekimi S. The genetics of caloric restriction in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1998;95(22):13091–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jiang YZ, Yan FX, Feng ZP, Lazarovici P, Zheng WH. Signaling network of forkhead family of transcription factors (FOXO) in dietary restriction. Cells. 2020;9(1):100.

    Article  CAS  Google Scholar 

  43. Takami G, Ota M, Nakashima A, Kaneko YS, Mori K, Nagatsu T, et al. Effects of atypical antipsychotics and haloperidol on PC12 cells: only aripiprazole phosphorylates AMP-activated protein kinase. J Neural Transm. 2010;117(10):1139–53.

    Article  CAS  PubMed  Google Scholar 

  44. Ota A, Nakashima A, Kaneko YS, Mori K, Nagasaki H, Takayanagi T, et al. Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells. J Neural Transm. 2012;119(11):1327–42.

    Article  CAS  PubMed  Google Scholar 

  45. Ye XL, Linton JM, Schork NJ, Buck LB, Petrascheck M. A pharmacological network for lifespan extension in Caenorhabditis elegans. Aging Cell. 2014;13(2):206–15.

    Article  CAS  PubMed  Google Scholar 

  46. Osuna-Luque J, Rodriguez-Ramos A, Gamez-del-Estal MD, Ruiz-Rubio M. Behavioral mechanisms that depend on dopamine and serotonin in Caenorhabditis elegans interact with the antipsychotics risperidone and aripiprazole. J Exp Neurosci. 2018;12:1179069518798628.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lucanic M, Garrett T, Yu I, Calahorro F, Asadi Shahmirzadi A, Miller A, et al. Chemical activation of a food deprivation signal extends lifespan. Aging Cell. 2016;15(5):832–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Raizen DM, Lee RYN, Avery L. Interacting genes required for pharyngeal excitation by motor-neuron MC in Caenorhabditis-elegans. Genetics. 1995;141(4):1365–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Greer EL, Brunet A. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell. 2009;8(2):113–27.

    Article  CAS  PubMed  Google Scholar 

  50. Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, et al. PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J. 2010;29(2):469–81.

    Article  CAS  PubMed  Google Scholar 

  51. Pan B, Chen J, Lian J, Huang XF, Deng C. Unique effects of acute aripiprazole treatment on the dopamine D2 receptor downstream cAMP-PKA and Akt-GSK3beta signalling pathways in rats. PLoS One. 2015;10(7):e0132722.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Zhang B, Jun H, Wu J, Liu J, Xu XZS. Olfactory perception of food abundance regulates dietary restriction-mediated longevity via a brain-to-gut signal. Nat Aging. 2021;1(3):255–68.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Petrascheck M, Ye XL, Buck LB. An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature. 2007;450(7169):553–U12.

    Article  CAS  PubMed  Google Scholar 

  54. Rangaraju S, Solis GM, Andersson SI, Gomez-Amaro RL, Kardakaris R, Broaddus CD, et al. Atypical antidepressants extend lifespan of Caenorhabditis elegans by activation of a non-cell-autonomous stress response. Aging Cell. 2015;14(6):971–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Srivastava D, Arya U, SoundaraRajan T, Dwivedi H, Kumar S, Subramaniam JR. Reserpine can confer stress tolerance and lifespan extension in the nematode C-elegans. Biogerontology. 2008;9(5):309–16.

    Article  CAS  PubMed  Google Scholar 

  56. Miller HA, Huang S, Schaller ML, Dean ES, Tuckowski AM, Munneke AS, et al. Serotonin and dopamine modulate aging in response to food perception and availability. bioRxiv. 2021;2021.03.23.436516.

  57. Donohoe DR, Aamodt EJ, Osborn E, Dwyer DS. Antipsychotic drugs disrupt normal development in Caenorhabditis elegans via additional mechanisms besides dopamine and serotonin receptors. Pharmacol Res. 2006;54(5):361–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Weeks KR, Dwyer DS, Aamodt EJ. Antipsychotic drugs activate the C. elegans Akt pathway via the DAF-2 insulin/IGF-1 receptor. ACS Chem Neurosci. 2010;1(6):463–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Nasrallah HA, Newcomer JW, Risinger R, Du YC, Zummo J, Bose A, et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiat. 2016;77(11):1519.

    Article  Google Scholar 

  60. Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329–47.

    Article  CAS  PubMed  Google Scholar 

  61. Mucci A, Piegari G, Galderisi S. Cognitive-enhancing effects of aripiprazole: a case report. Clin Pract Epidemiol Ment Health. 2008;4:24.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Koprivica V, Regardie K, Wolff C, Fernalld R, Murphy JJ, Kambayashi J, et al. Aripiprazole protects cortical neurons from glutamate toxicity. Eur J Pharmacol. 2011;651(1-3):73–6.

    Article  CAS  PubMed  Google Scholar 

  63. De Deyn PP, Drenth AFJ, Kremer BP, Voshaar RCO, Van Dam D. Aripiprazole in the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2013;14(4):459–74.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Prof. Garry Wong at the University of Macau for the critical reading of this manuscript and Shuai Li and Wenshu Zhou for help with experiments. All strains were provided by the CGC, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440).

Funding

WHZ was supported by grants from the National Natural Science Foundation of China (grant No. 31771128 and 32070969), The Science and Technology Development Fund, Macau SAR (File No. 0127/2019/A3, 0044/2019/AGJ, and 0113/2018/A3), and University of Macau (File No. MYRG2018-00134-FHS and MYRG2020-00158-FHS). STH was supported by grants from the National Natural Science Foundation of China (grant No. 81871026), Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions (2021SHIBS0002), Shenzhen Science and Technology Innovation Committee Research Grants (JCYJ20180504165806229; KQJSCX20180322151111754), and SUSTech-UQ Joint Center for Neuroscience and Neural Engineering (CNNE).

Author information

Authors and Affiliations

  1. Centre of Reproduction, Development & Aging and Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau, China

    Yizhou Jiang, Uma Gaur, Zhibai Cao & Wenhua Zheng

  2. Brain Research Centre and Department of Biology, Southern University of Science and Technology, 1088 Xueyuan Blvd, Nanshan District, Shenzhen, Guangdong Province, China

    Yizhou Jiang & Sheng-Tao Hou

Authors
  1. Yizhou Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uma Gaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhibai Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sheng-Tao Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenhua Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y.J., S.H., and W.Z provided conceptualization. Y.J. conducted the experiments and analyzed the data. U.G. and Z.C. assisted in methodology and experiments. Y.J. wrote the first draft of the manuscript. S.T. and W.Z. provided funding and revised the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Sheng-Tao Hou or Wenhua Zheng.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

List of C. elegans strains used in this study.

Additional file 2: Table S2.

Supporting data.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, Y., Gaur, U., Cao, Z. et al. Dopamine D1- and D2-like receptors oppositely regulate lifespan via a dietary restriction mechanism in Caenorhabditis elegans. BMC Biol 20, 71 (2022). https://doi.org/10.1186/s12915-022-01272-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12915-022-01272-9

Keywords

  • Dopamine
  • Lifespan
  • Caenorhabditis elegans
  • Aripiprazole
  • Dietary restriction

BMC Biology

ISSN: 1741-7007

Contact us